Vasoactive intestinal peptide receptor subtypes and signalling pathways involved in relaxation of human stomach.

Severi C, Tattoli I, Corleto VD, Maselli MA, Trisolini P, Delle Fave G

Neurogastroenterology and motility1 Nov 2006Cited by 10 (Europe PMC)

PMID17040412DOI10.1111/j.1365-2982.2006.00822.xPepBankPUB-17040412

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

2 results from studies that gave the peptide. No result from this study comes from people.

01LabEx vivo tissueActivity measurement
In human stomach smooth muscle, VIP caused greater relaxation of antrum cells and strips than fundus, with a lower ED50 in the antrum.
In plain wordsIn lab tests on human stomach muscle, VIP relaxed the antrum more strongly and at a lower dose than the fundus.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableVIP-induced relaxation of antrum versus fundus
Study
humann: not reported in source
Human fundus and antrum smooth muscle cells and strips
Comparator
Fundus
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
Dose not stated
Measurements
ED50
0.53 nmol L(-1)
antrum
ED50
3.4 nmol L(-1)
fundus
Source sentences
Summary
VIP caused greater relaxation of smooth muscle cells (SMC) and strips of the antrum presenting on the former a higher efficacy and potency (ED(50): 0.53 +/- 0.17 nmol L(-1)) than on the fundus (ED(50): 3.4 +/- 1.4 nmol L(-1)).
1 context sentence(design, population, supporting numbers)
Summary · context
This study aimed at investigating, in terms of biological activity, receptor expression and related signalling pathways, the action of VIP separately on the human fundus and the antrum.
Report a problemFND-1704041201
02LabEx vivo tissueMechanism
In human fundus and antrum strips, the VIP effect was not blocked by tetrodotoxin.
In plain wordsIn lab tests on human stomach muscle strips, tetrodotoxin did not block the effect of VIP.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeEffect of tetrodotoxin on VIP relaxation
Study
humann: not reported in source
Human fundus and antrum smooth muscle cells and strips
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
On both fundus and antrum strips, its effect was tetrodotoxin insentitive.
1 context sentence(design, population, supporting numbers)
Summary · context
This study aimed at investigating, in terms of biological activity, receptor expression and related signalling pathways, the action of VIP separately on the human fundus and the antrum.
Report a problemFND-1704041202

Studies that did not test the peptide alone3

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

03LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueMechanism
In human stomach, only VPAC2 and natriuretic peptide clearance receptors were expressed, with VPAC2 more abundant in the antrum.
In plain wordsIn human stomach tissue, VPAC2 was the only VIP receptor found, and it was more abundant in the antrum.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableVIP receptor expression in human stomach
Study
humann: not reported in source
Human fundus and antrum smooth muscle cells and strips
Outcome group
Receptor activity and mechanism · Gastrointestinal
Source sentences
Summary
Reverse transcriptase-polymerase chain reaction analysis showed the sole expression of VPAC2 and natriuretic peptide clearance receptors, with VPAC2 being more abundant in the antrum.
1 context sentence(design, population, supporting numbers)
Summary · context
This study aimed at investigating, in terms of biological activity, receptor expression and related signalling pathways, the action of VIP separately on the human fundus and the antrum.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1704041203
04LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueMechanism
Modulators of the cAMP pathway had more pronounced effects on antrum smooth muscle cells than on fundus cells.
In plain wordsIn lab tests on human stomach muscle cells, drugs that act on the cAMP pathway had stronger effects in the antrum.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicablecAMP-pathway modulators on antrum versus fundus cells
Study
humann: not reported in source
Human fundus and antrum smooth muscle cells and strips
Outcome group
Receptor activity and mechanism · Gastrointestinal
Source sentences
Summary
Activation of the cAMP-pathway by forskolin or its inhibition by adenylate cyclase (2'5'-dideoxyadenosine) or kinase (Rp-cAMPs) inhibitors had more pronounced effects on antrum SMC.
1 context sentence(design, population, supporting numbers)
Summary · context
This study aimed at investigating, in terms of biological activity, receptor expression and related signalling pathways, the action of VIP separately on the human fundus and the antrum.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1704041204
05LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueMechanism
Modulators of the cGMP pathway had more effect on fundus smooth muscle cells, which also had higher endothelial nitric oxide synthase expression.
In plain wordsIn lab tests on human stomach muscle cells, drugs that act on the cGMP pathway had stronger effects in the fundus.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicablecGMP-pathway modulators and eNOS expression on fundus versus antrum
Study
humann: not reported in source
Human fundus and antrum smooth muscle cells and strips
Outcome group
Receptor activity and mechanism · Gastrointestinal
Source sentences
Summary
Activation of the cGMP-pathway by sodium nitroprusside or its inhibition by guanylate cyclase (LY83583) or kinase (KT5823) inhibitors had more effects on fundus SMC, on which a higher expression of endothelial nitric oxide synthase was found.
1 context sentence(design, population, supporting numbers)
Summary · context
This study aimed at investigating, in terms of biological activity, receptor expression and related signalling pathways, the action of VIP separately on the human fundus and the antrum.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1704041205

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.